Comparison of surgical approaches to radical prostatectomy in our series beyond oncological and functional outcomes

Mar 5, 2022 | Magazine: Actas Urológicas Españolas

Á García Cortés 1 , J Colombás Vives 2 , C Gutiérrez Castañé 2 , S Chiva San Román 2 , P Doménech López 2 , F J Ancizu Marckert 2 , M Hevia Suárez 3 , I Merino Narro 4 , J M Velis Campillo 5 , F Guillén Grima 6 , M Torres Roca 2 , F Diez-Caballero Y Alonso 2 , D Rosell Costa 2 , F Villacampa Aubá 2 , F R de Fata Chillón 2 , G Andrés Boville 2 , G Barbas Bernardos 2 , B Miñana López 2 , J E Robles García 2 , J I Pascual Piédrola 2

Objectives
To evaluate the outcomes of robot-assisted radical prostatectomy (RARP) compared to those of open (ORP) and laparoscopic (LRP) surgery. The interest lies fundamentally in the quality-of-life (QoL) evaluation, postoperative recovery, and personal satisfaction of patients with the intervention (PS) beyond oncological and functional outcomes.

Methods
Six hundred eighty-five RPs were performed in our center between 2011–2018 (17,8% ORP, 22,2% LRP and 60% RARP). Patients were prospectively assessed through follow-up until April 2020 and a multiple questionnaire at 12-months post-RP that included ICIQ-SF, SHIM, IPSS, IQL and questions about pain, postoperative recovery and PS. Also baseline and postoperative patient- and treatment-related data were collected, and binomial logistic regressions were performed for the 1 vs.1 comparisons (ORP vs. RARP and LRP vs. RARP).

Results
RARP patients have overall fewer comorbidities, less tumor aggressiveness, more operative time requirements and more positive surgical margins than ORP and LRP patients. Nevertheless, RARP outperforms ORP in: hospital stay (days) (OR 0,86; 95% CI: 0,80–0,94), hemoglobin loss (OR 0,38; 95% CI: 0,30–0,47), transfusion rate (OR 0,18; 95% CI: 0,09–0,34), early complications (p = 0,001), IQL (OR 0,82; 95% CI: 0,69–0,98), erectile function (OR 0,41; 95% CI: 0,21–0,79), pain control (OR 0,82; 95% CI: 0,75–0,89), postoperative recovery (p < 0,001) and choice of a different approach (OR 5,55; 95% CI: 3,14–9,80). RARP is superior to LRP in: urinary continence (OR 0,55; 95% CI: 0,37–0,82), IPSS (OR 0,96; 95% CI: 0,93–0,98), IQL (OR 0,76; 95% CI: 0,66–0,88), erectile function (OR 0,52; 95% CI: 0,29–0,93), postoperative recovery (p = 0,02 and 0,004), PS (p = 0,005; 0,002; and 0,03) and choice of a different approach (OR 7,79; 95% CI: 4,63–13,13).

Conclusions
The findings of our study globally endorse a positive effectiveness of RARP over ORP and/or LRP, both on functional issues, postoperative recovery, QoL and PS. Oncologic results should still be improved.

CITATION Actas Urol Esp (Engl Ed). 2022 Jun;46(5):275-284.
doi: 10.1016/j.acuroe.2021.12.001. Epub 2022 Mar 5.

see publication in pubmed